Development of a non-transformed human liver cell line with differentiated-hepatocyte and urea-synthetic functions: Applicable for bioartificial liver

International Journal of Artificial Organs

Volumn 22, Issue 11, 1999, Pages 769-777

  Yoon, J H ^a   Lee, Hyo V Suk ^a,b   Lee, J S ^a   Park, J B ^a   Kim, C Y ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Albumin; Bioartificial liver; Butyrate; Cytochrome P450; Hepatocyte; Urea

Indexed keywords

ARTIFICIAL ORGANS; CELL CULTURE; CELLS; METABOLISM;

ALBUMIN; BIOARTIFICIAL LIVER; BUTYRATE; CELL CYCLE; CELL LINES; CYTOCHROMES P450; HEPATOCYTES; HUMAN HEPATOCYTES; HUMAN LIVER CELLS; SODIUM BUTYRATE;

UREA;

ALBUMIN; ALPHA FETOPROTEIN; BUTYRIC ACID; CYTOCHROME P450; MESSENGER RNA; RIFAMPICIN; UREA;

ARTICLE; ARTIFICIAL LIVER; CARCINOGENICITY; CELL CYCLE G2 PHASE; CELL GROWTH; CELL LINE; CONTROLLED STUDY; ENZYME ACTIVITY; FETUS LIVER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER DEVELOPMENT; NONHUMAN; NUDE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UREA CYCLE;

EID: 0033458894     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139889902201111     Document Type: Article

References (37)

1. Rozga J, Williams F, Ro MS, et al. Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells. Hepatology 1993; 17: 258-65.
2. Nyberg SL, Peshwa MV, Payne WD, Hu WS, Cerra FB. Evolution of the boartificial liver: the need for randomized clinical trials. Am J Surg 1993; 166: 512-21.
3. Hughes RD, Williams R. Assessment of bioartificial liver support in acute liver failure. Int J Artif Organs 1996; 19:3-6.
4. Stange J, Mitzner S. Cell sources for bioartificial liver support. Int J Artif Organs 1996; 19: 14-7.
5. Riordan S, Willams R. Bioartificial liver support: developments in hepatocyte culture and bioreactor design. Br Med Bull 1997; 53: 730-44.
6. Stange J, Mitzner S, Strauss M, et al. Primary or established liver cells for a hybrid liver? Comparison of metabolic features. ASAIO J 1995; 41: M310-5.
7. Enosawa S, Suzuki S, Kakefuda T, Amemiya H. Examination of 7-ethoxycoumarin deethylation and ammonia removal activities in 31 hepatocyte cell lines. Cell Transplant 1996; 5: S39-40.
8. Nyberg SL, Remmel RP, Mann HJ, Peshwa MV, Hu WS, Cerra FB. Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver. Ann Surg 1994; 220: 59-67.
9. te Velde AA, Flendrig LM, Ladiges NC, Chamuleau RA. Immunological consequences of the use of xenogeneic hepatocytes in a bioartificial liver for acute liver failure. Int J Artif Organs 1997; 20: 229-33.
10. Arkadopoulos N, Detry O, Rozga J, Demetriou AA. Liver assist systems: state of the art. Int J Artif Organs 1998; 21: 781-7.
11. Tada S, Saito H, Ebinuma H, et al. Reduction of LAK-sensitivity and changes in antigen expression on hepatoma cells by sodium butyrate. Cancer Biochem Biophys 1996; 15: 179-88.
12. Saito H, Tada S, Ebinuma H, et al. Changes of antigen expression on human hepatoma cell lines caused by sodium butyrate, a differentiation inducer. J Gastroenterol 1994; 29: 733-9.
13. Saito H, Morizane T, Watanabe T, et al. Differentiating effect of sodium butyrate on human hepatoma cell lines PLC/PRF/5, HCC-M and HCC-T. Int J Cancer 1991; 48: 291-6.
14. Saito H, Kagawa T, Tada S, et al. Effect of dexamethasone, dimethylsulfoxide and sodium butyrate on human hepatoma cell line PLC/PRF/5. Cancer Biochem Biophys 1996; 15: 179-88.
15. Leder A, Leder P. Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells. Cell 1975; 5: 319-22.
16. Gum JR, Kam WK, Byrd JC, Hicks JW, Sleisenger MH, Kim YS. Effect of sodium butyrate on human colonic adenocarcinoma cells: induction of placental-like alkaline phosphatase. J Biol Chem 1987; 262: 1092-7.
17. Langdon SP, Hawkes MM, Hay FG, et al. Effect of sodium butyrate and other differentiation inducer on poorly differentiated human ovarian adenocarcinoma cell lines. Cancer Res 1988; 48: 6161-5.
18. Tsutsumi T, Ido A, Nakao K, et al. Reciprocal regulation of alpha-fetoprotein and albumin gene expression by butyrate in human hepatoma cells. Gastroenterology 1994; 107: 499-504.
19. Bartalena L, Bogazzi F, Donadel G, Martino E, Gabrielli F, Pinchera A. The differentiation-inducing agent sodium butyrate produces divergent effects on albumin and thyroxine-binding globulin synthesis by human hepatoblastoma-derived (Hep G2) cells. J Endocrinol Invest 1990; 13: 917-22.
20. Park J, Lee H-S, Park JB, Kim CY. Establishment of continuous human fetal hepatocyte cell line by transfection of simian virus 40 T gene. Mol Cells 1996; 6: 534-40.
21. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-9.
22. Kono Y, Yang S, Letarte M, Roberts EA. Establishment of a human hepatocyte line derived from primary culture in a collagen gel sandwich culture system. Exp Cell Res 1995; 221:478-85.
23. Niwa Y, Matsumura M, Shiratori Y, et al. Quantitation of alpha-fetoprotein and albumin messenger RNA in human hepatocellular carcinoma. Hepatology 1996; 23: 1384-92.
24. Matsumura M, Niwa Y, Hikiba Y, et al. Sensitive assay for detection of hepatocellular carcinoma associated gene transcription (alpha-fetoprotein mRNA) in blood. Biochem Biophys Res Commun 1995; 207: 813-8.
25. Kowalski-Saunders PW, Winwood PJ, Arthur MJP, Wright R. Reversible inhibition of albumin production by rat hepatocyte maintained on a laminin-rich gel (Engelbreth-Holm-Swarm) in response to secretory products of Kupffer cells and cytokines. Hepatology 1992; 16: 733-41.
26. Molowa DT, Schuetz EG, Wrighton SA, et al. Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. Proc Natl Acad Sci USA 1986; 83: 5311-5.
27. Lennard MS, Crewe HK, Tucker GT, Woods HF. Metoprolol oxidation by rat liver microsomes. Inhibition by debrisoquine and other drugs. Biochem Pharmacol 1986; 35: 2757-61.
28. Freshney RI. Culture of animal cells. 3rd ed. New York: Wiley-Liss, 1994; 91-3.
29. Salyers AA, Leedle JAZ. Carbohydrate metabolism in the human colon. In: Hentges DJ, ed. Human intestinal microflora in health and disease. New York: Academic, 1983; 129-46.
30. Cummings JH, Pomare EW, Branch WJ, Naylor CPE. Short chain fatty acids in human intestine, portal, hepatic and venous blood. Gut 1987; 28: 1221-7.
31. Daniel P, Brazier M, Cerutti I, et al. Pharmacokinetic study of butyric acid administrated in vivo as sodium and arginine butyrate salts. Clin Chim Acta 1989; 181: 255-64.
32. Wang X-M, Wang X, Li J, Evers BM. Effects of 5-azacytidine and butyrate on differentiation and apoptosis of hepatic cancer cell lines. Ann Surg 1998; 227: 922-31.
33. Barnard JA, Warwick G. Butyrate rapidly induces growth inhibition and differentiation in HT29 cells. Cell Growth Differ 1993; 4: 495-501.
34. Heerdt BG, Houston MA, Augenlicht LH. Short-chain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function. Cell Growth Differ 1997; 8: 523-32.
35. Saito H, Ebinuma H, Takahashi M, et al. Loss of butyrate-induced apoptosis in human hepatoma cell lines HCC-M and HCC-T having substantial Bcl-2 expression. Hepatology 1998; 27: 1233-40.
36. Zucker SD, Gallan JL. Physiology of the liver. In: Haubrich WS, Schaffner F, eds. Bockus Gastroenterology. Volume 3.5th ed. Philadelphia: WB Saunders, 1995; 1858-905.
37. Naik S, Santangini HA, Trenkler DM, et al. Functional recovery of porcine hepatocytes after hypothermic or cryogenic preservation for liver support systems. Cell Transplant 1997; 6: 447-54.